PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of patients with HER2+ early breast cancer (EBC) at high risk of recurrence.1
See the PERJETA iDFS and OS data
iDFS primary analysis and OS first interim analysis at 3 years, and iDFS exploratory follow-up analysis and OS exploratory final analysis at 10 years
See the updated recommendation from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)